Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Transcutaneous nitroglycerin evaluated in controlled trial for MED

March 9, 1999

Fluvastatin induces delayed improvement in coronary flow reserve

March 9, 1999

Hemosol successfully completes phase II trial of Hemolink in CABG patients

March 8, 1999

Rhone-Poulenc Rorer describes new hypoglycemic series

March 5, 1999

Lilly's recombinant glucagon now being launched, will replace animal-derived product

March 4, 1999

AC-2993 advances to clinical trials in type II diabetes

March 4, 1999

Preclinical results obtained with candidate antidiabetic support further testing

March 3, 1999

Vitronectin receptor antagonists with a benzocycloheptene core designed at SB

March 3, 1999

Novel vitamin D compounds with favorable biological profile from WARF

March 3, 1999

Novel hypoglycemic compounds designed at RPR

March 3, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
Will Ovid’s golden age of KCC2 metamorph CNS?
BioWorld
The “deep dive” April 8 by Ovid Therapeutics Inc. into potassium-chloride co-transporter 2 (KCC2) research included company officials and independent experts in...